Targeting down-regulation of YTHDF2 increases the stability of m6A-modified GSK3β mRNA and inhibits the Wnt/β-catenin/Cyclin D1 pathway, which in turn prevents CRC cell proliferation.73 But by identifying its m6A mutation, YTHDF2 may also control the degradation of circYAP1, which prevents CRC cells from proliferating, invading, migrating, and escaping the immune system.74 The diverse kinds of m6A modified RNAs that YTHDF2 targets in various illness contexts and cellular settings may be the cause of this dual impact. The gene discussed is CCND1; the disease is colorectal carcinoma.